Scholar Rock heads into September with a notable tension at its core: a strong one-month rally of 18% sits alongside short interest that has quietly ground higher, an activist on the register, and a pair of institutional holders trimming meaningfully.
Short interest has risen to nearly 18% of free float — a level that reflects genuine scepticism about the apitegromab story rather than routine hedging. The position has grown steadily, up around 3.7% over the past week to approximately 18.3 million shares. Yet the borrow market itself is not signalling alarm. Availability is ample at roughly 360% of short interest — well into the "normal" range — meaning new shorts face no friction entering the trade. Cost to borrow has nudged higher, now at 0.55%, up about 15% on the week, but remains firmly in "easy borrow" territory. The ORTEX short score has been drifting upward all month, reaching 71.98 — placing the stock in the bottom 10th percentile on short score rank — but the combination of generous availability and low borrowing costs suggests this is a conviction short thesis, not a squeezed one. Options lean modestly bullish: the put/call ratio at 0.52 is running slightly above its 20-day average of 0.47, but a z-score of 0.75 puts that well within normal range. No hedge panic here.
The Street remains broadly constructive. Following the August 6 earnings print — which drew a 10.5% one-day gain — JP Morgan raised its target from $56 to $63 while maintaining Overweight, and Citi lifted from $58 to $60. Multiple firms reiterated Buy-equivalent ratings, leaving the consensus mean target at $60.75 against a current price of $55.89, implying about 8% upside. The bull case centres on apitegromab as a muscle-directed complement to existing SMA treatments, with forward EPS revisions running sharply positive — the eps_12m_fwd_yoy_increase factor ranks in the 93rd percentile. Bears push back on valuation: price-to-book is elevated at 25x, EV/EBITDA is deeply negative, and the standard biotech caution around regulatory and manufacturing risk applies. EPS momentum scores are soft, ranking 28th-32nd percentile on both 30- and 90-day horizons, suggesting consensus upgrades have slowed after the initial post-trial burst.
The ownership picture is where the week's most interesting signal sits. A Schedule 13D/A filing from Srinivas Akkaraju — a known biotech investor — is on the register at 7.2% of the class, marking him as an activist holder by SEC classification. That disclosure dates to October 2025, so it is not fresh news, but it remains live. More notable are recent flows around the 5% threshold: Invus Public Equities (filing as Artal Group in the institutional data) trimmed from 11.4% to 8.0% of the class as of a mid-August filing, and Redmile Group cut its stake roughly in half, from 7.6% to 3.6%, dropping below the 5% disclosure threshold. FMR (Fidelity), by contrast, added 752,000 shares and now holds just under 15% — the largest single reported position. BlackRock added over 2 million shares. The pattern is a split between index and large active managers building, and earlier-stage biotech specialists reducing. As always, 13D/G positions are as-last-disclosed and holders below 5% may exit without further filing.
Insider data is stale — the most recent Form 4 activity on file dates to late January 2026, over seven months ago, and involved routine plan-based sales by scientific and medical officers. Nothing in that record changes the current picture materially.
The next earnings event is pencilled in for November 11. Between now and then, the story is essentially a waiting game on apitegromab's commercial trajectory and any regulatory updates — with 18% short interest, a high-conviction activist holder, and two large specialists trimming, the range of outcomes around any binary catalyst remains wide.
See the live data behind this article on ORTEX.
Open SRRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
